TaiGen Biopharmaceuticals Holdings Statistics

Total Valuation

TaiGen Biopharmaceuticals Holdings has a market cap or net worth of TWD 10.27 billion. The enterprise value is 9.23 billion.

Market Cap	10.27B
Enterprise Value	9.23B

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

TaiGen Biopharmaceuticals Holdings has 717.84 million shares outstanding. The number of shares has increased by 0.11% in one year.

Shares Outstanding	717.84M
Shares Change (YoY)	+0.11%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	2.32%
Owned by Institutions (%)	5.91%
Float	423.00M

Valuation Ratios

The trailing PE ratio is 43.84.

PE Ratio	43.84
Forward PE	n/a
PS Ratio	68.62
PB Ratio	8.76
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	39.25
EV / Sales	61.75
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-46.62

Financial Position

The company has a current ratio of 20.34, with a Debt / Equity ratio of 0.06.

Current Ratio	20.34
Quick Ratio	19.37
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.34
Interest Coverage	-99.54

Financial Efficiency

Return on equity (ROE) is 22.14% and return on invested capital (ROIC) is -8.73%.

Return on Equity (ROE)	22.14%
Return on Assets (ROA)	-8.42%
Return on Capital (ROIC)	-8.73%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.13
Inventory Turnover	0.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.05% in the last 52 weeks. The beta is 0.76, so TaiGen Biopharmaceuticals Holdings's price volatility has been lower than the market average.

Beta (5Y)	0.76
52-Week Price Change	-3.05%
50-Day Moving Average	14.38
200-Day Moving Average	14.90
Relative Strength Index (RSI)	45.14
Average Volume (20 Days)	1,011,270

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TaiGen Biopharmaceuticals Holdings had revenue of TWD 149.45 million and earned 235.16 million in profits. Earnings per share was 0.33.

Revenue	149.45M
Gross Profit	136.03M
Operating Income	-158.77M
Pretax Income	239.23M
Net Income	235.16M
EBITDA	-149.56M
EBIT	-158.77M
Earnings Per Share (EPS)	0.33

Full Income Statement

Balance Sheet

The company has 1.10 billion in cash and 66.74 million in debt, giving a net cash position of 1.04 billion or 1.44 per share.

Cash & Cash Equivalents	1.10B
Total Debt	66.74M
Net Cash	1.04B
Net Cash Per Share	1.44
Equity (Book Value)	1.17B
Book Value Per Share	1.63
Working Capital	1.12B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -196.93 million and capital expenditures -1.04 million, giving a free cash flow of -197.97 million.

Operating Cash Flow	-196.93M
Capital Expenditures	-1.04M
Free Cash Flow	-197.97M
FCF Per Share	-0.28

Full Cash Flow Statement

Margins

Gross margin is 91.02%, with operating and profit margins of -106.23% and 157.35%.

Gross Margin	91.02%
Operating Margin	-106.23%
Pretax Margin	160.07%
Profit Margin	157.35%
EBITDA Margin	-100.07%
EBIT Margin	-106.23%
FCF Margin	-132.46%

Dividends & Yields

TaiGen Biopharmaceuticals Holdings does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.11%
Shareholder Yield	-0.11%
Earnings Yield	2.28%
FCF Yield	-1.93%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TaiGen Biopharmaceuticals Holdings has an Altman Z-Score of 59.59.

Altman Z-Score	59.59
Piotroski F-Score	n/a